SCHEMBL2827973

SCHEMBL2827973

CCOC(=O)c1ccc(NC(=O)c2cc(NS(=O)(=O)c3ccc(Cl)c(Cl)c3)c(OC)c(OC)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CPT2 P23786 1/20 0.56
CPT1A P50416 1/20 0.56
ALDH1A1 P00352 8/20 0.56
LMNA P02545 4/20 0.56
KDM4E B2RXH2 3/20 0.56
HPGD P15428 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 4/20 0.51
MAPK1 P28482 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.49
ABCG2 Q9UNQ0 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2825172 0.89 CPT2 (0.61) CPT2CPT1AALDH1A1LMNAKDM4E
SCHEMBL2828139 0.89 CPT2 (0.60) CPT2CPT1AALDH1A1LMNAKDM4E
SCHEMBL2824492 0.88 CPT2 (0.72) CPT2CPT1AALDH1A1LMNAKDM4E
SCHEMBL2828276 0.88 LMNA (0.69) CPT2CPT1AALDH1A1LMNAKDM4E
SCHEMBL2825880 0.88 CPT1A (0.69) CPT2CPT1AALDH1A1LMNAKDM4E
SCHEMBL2825039 0.87 CPT2 (0.58) CPT2CPT1AALDH1A1LMNAKDM4E
SCHEMBL2827310 0.85 CPT1A (0.79) CPT2CPT1AALDH1A1LMNAKDM4E
SCHEMBL3559043 0.83 NPSR1 (0.56) CPT2CPT1AALDH1A1HPGDSMN1; SMN2
SCHEMBL3553138 0.81 LMNA (0.65) ALDH1A1LMNAKDM4ESMN1; SMN2MAPT
SCHEMBL1458653 0.80 MAPT (0.70) ALDH1A1LMNAHPGDSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232104-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD (DE) 2012-09-13 US disclosed
US-20110319438-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD (DE) 2011-12-29 US disclosed
US-20100144762-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD 2010-06-10 US disclosed
US-7723538-B2 enzyme inhibitors of membrane-bound carnitine-dependent palmitoyltransferases (CPTs); inhibit gluconeogenesis and therefore counteract hyperglycemia; 4-(3-Benzenesulfonylamino-benzoylamino)-benzoic acid HOFFMANN-LA ROCHE INC. (US) 2010-05-25 US disclosed
EP-1891001-B1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS HOFFMANN LA ROCHE (CH) 2010-05-05 EP disclosed
EP-1891001-A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS F. Hoffmann-Roche AG (CH) 2008-02-27 EP disclosed
WO-2006131452-A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-12-14 WO disclosed
US-20060276494-A1 Novel sulfonamides as L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276494-A1 Novel sulfonamides as L-CPT1 inhibitors CPT1A, CPT1B, CPT2 CPT2 3/4885CPT1A 1/4885ALDH1A1 216/4885
US-20120232104-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS CPT1A, CPT1B, CPT2 CPT2 3/4885CPT1A 1/4885ALDH1A1 216/4885
US-20100144762-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS CPT1A, CPT1B, CPT2 CPT2 3/4885CPT1A 1/4885ALDH1A1 216/4885
US-20110319438-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS CPT1A, CPT1B, CPT2 CPT2 3/4885CPT1A 1/4885ALDH1A1 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.